Guy Young/LinkedIn
Jan 2, 2026, 03:50
Emicizumab in Infants: Not Just Cost-effective but Mandatory
Flora Peyvandi, Professor of Internal Medicine at the University of Milan and former President of ISTH, shared a post on X:
“Emicizumab in infants: not just cost-effective but mandatory.”
Author: Guy Young
Read the full article.
More posts by Flora Peyvandi on Hemostasis Today.
-
Jul 8, 2026, 19:50Heghine Khachatryan: Why the EHC Fully Supports the Lancet Commission on Women’s Hematological Health
-
Jul 8, 2026, 19:40Autoregulation Failure in SVD and Cognitive Impairment – International Journal of Stroke
-
Jul 8, 2026, 19:30Ahmed Mostafa: Why Antibodies Cause Organ Rejection
-
Jul 8, 2026, 19:28Erika Bocanegra: Witnessing 25 Years of Progress in Bleeding Disorders Care
-
Jul 8, 2026, 19:27Ahmadou Ouedraogo: Do You Know Your Blood Type?
-
Jul 8, 2026, 19:26Javed Anees: An Evidence-Based Clinical Guide to ESA Therapy
-
Jul 8, 2026, 19:25Paul Breillat: Nature Reviews Rheumatology Highlights Our VEXAS Syndrome Research
-
Jul 8, 2026, 19:25Luca Saba: Why Does the Same Patient Have Different Plaque in Different Arteries?
-
Jul 8, 2026, 19:25Luisa Weiss: Understanding the Molecular Differences Between Acute and Chronic Coronary Syndromes.